Indi Molecular Closes Sale of PCC Technology Platform

Today Indi Molecular announced the successful close of the sale of its PCC technology platform. The company retains two powerful, advanced PCC molecules targeting ovarian and pancreatic cancer, respectively. 

PCC technology, originally developed with Caltech, allows for the rapid discovery and production of a synthetic class of binding agents with antibody-like properties. PCC molecule’s small size makes them a synthetic equivalent of a monoclonal antibody but with biophysical properties similar to a small molecule drug. PCCs offer the promise of superior performance, stability, lower cost and faster creation compared to monoclonal antibodies